Attendee search 

Kairos Therapeutics has developed a proprietary next generation antibody-drug conjugate (ADC) platform based on novel toxin, linker and site-specific conjugation technology. Kairos has demonstrated superior pre-clinical in-vivo efficacy over T-DM1. Further pre-clinical studies demonstrate Kairos’ ADCs have superior tolerability and therapeutic index, compared to other leading platforms which may lead to greater clinical efficacy. Through key partnerships, Kairos is developing a novel therapeutic pipeline and is out-licensing its ADC platform to companies seeking access to state-of-the-art technology.  

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick NJ with an Innovation Center in Cambridge MA. The firm invests in a variety of fields within the life science sector including medical devices. J&J?s medical device investments are highly varied in both size and structure, the structure may involve milestone payments or may be an equity investment. J&J is interested in early stage medical device companies located globally.

NSF Health Sciences offers clinical, regulatory, and quality consulting services across the total product lifecycle for innovative medical device, pharmaceutical, and biotechnology companies.  We specialize in helping companies balance FDA and worldwide regulatory requirements with their business needs. 

Healthcare Software focusing in on Mental health & Addictions. The main goal is to place these individuals on a path to recovery.

TREAT product line is commercially available as an EHR serving the unique needs of community behavioral health, rehabilitation, and other community-based providers. The design of our system is centered on a client-centered recovery model principle with best practice assessments linked to an interdisciplinary plan of care which is at the core of our methodology. TREAT’s modules create a record of client care that functions at multiple levels and builds upon itself. From assessments, to care planning, to documentation, to decision support, TREAT provides an integrated solution centered on client care.

Assessment Tools

Our TREAT product has a catalog of over 120 different assessment tools, and can be customized to include new tools upon request. Assessments are linked with our Interdisciplinary Plan of Client Care (IPCC) and Progress Notes modules to offer a truly integrated approach to patient care.

Humabs BioMed is a profitable Swiss biotech company that is discovering and developing nature-selected human monoclonal antibodies using proprietary platforms. 

Humabs is currently focusing on the development of human antibodies to fight infectious diseases. Additional indications are being targeted at the discovery research stage.

Humabs has already achieved four major licensing deals with Pharmaceutical companies generating significant revenues in the form of near term revenues, as well as a stream of longer term milestones and royalties. Two of these programs are in clinical development phases.

Humabs is seeking additional investments to allow the company to bring selected programs into clinical research on its own, thus significantly increasing the added value.

Cavidi is a Swedish based diagnostic company that has developed a novel method for measuring HIV viral load in patients recieving anti-retroviral therapy for treatment of HIV. Viral load is a critical indicator of the effectiveness of HIV therapy, and has been the standard of care in the developed world for many years. Just recently the World Health Organization (WHO) updated its recommendations to include viral load for patients in the developing world where the vast majority of HIV patients exists, and a large influx of international funding has significantly increased aceess to HIV drugs. The Cavidi method is novel in that it measures the viral enzyme reverse transcriptase (RT), and not viral nucleic acid (RNA) by polymerase chain reaction (PCR). The Cavidi method is not subject to the logistical challenges of PCR such as contamination risk. The Cavidi RT assay is much less expensive and can be performed in labs that lack the sophisitication to perform technologies such as PCR. Therfore, the Cavidi assay significantly improves access to this vitally important technology. For the past several years a manual version of the Cavidi technology has been utilized in laboratories in the developing world. The performance of the assay has been validated vs the industry leading PCR methods in many peer review publications. The company is now seeking funding to develop an automated version of the assay that will make it more widely adaptable to many laborartories.